Arbutus Biopharma Q2 2024 GAAP EPS $(0.11) Misses $(0.10) Estimate, Sales $1.726M Miss $1.755M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma reported its Q2 2024 financial results, with a GAAP EPS of $(0.11), missing the $(0.10) estimate. Sales were $1.726 million, also missing the $1.755 million estimate.
August 01, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arbutus Biopharma's Q2 2024 financial results showed a GAAP EPS of $(0.11), missing the $(0.10) estimate, and sales of $1.726 million, missing the $1.755 million estimate. This underperformance may negatively impact the stock price in the short term.
The company's earnings and sales both missed analyst estimates, which is likely to be viewed negatively by investors. This could result in a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100